These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 33761389)

  • 1. Automated assessment of the substantia nigra on susceptibility map-weighted imaging using deep convolutional neural networks for diagnosis of Idiopathic Parkinson's disease.
    Shin DH; Heo H; Song S; Shin NY; Nam Y; Yoo SW; Kim JS; Yoon JH; Lee SH; Sung YH; Kim EY
    Parkinsonism Relat Disord; 2021 Apr; 85():84-90. PubMed ID: 33761389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A preliminary attempt to visualize nigrosome 1 in the substantia nigra for Parkinson's disease at 3T: An efficient susceptibility map-weighted imaging (SMWI) with quantitative susceptibility mapping using deep neural network (QSMnet).
    Jo M; Oh SH
    Med Phys; 2020 Mar; 47(3):1151-1160. PubMed ID: 31883389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging of nigrosome 1 in substantia nigra at 3T using multiecho susceptibility map-weighted imaging (SMWI).
    Nam Y; Gho SM; Kim DH; Kim EY; Lee J
    J Magn Reson Imaging; 2017 Aug; 46(2):528-536. PubMed ID: 27859983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective multi-centre study of susceptibility map-weighted MRI for the diagnosis of neurodegenerative parkinsonism.
    Sung YH; Kim JS; Yoo SW; Shin NY; Nam Y; Ahn TB; Yoo D; Lee KM; Kim HG; Koh SB; Kim J; Kim I; Kwon DY; Lee Y; Kim C; Chung SJ; Jo S; Lee SH; Kim SJ; Kim M; Lyoo CH; Baek MS; Kang SY; Chang SK; Jo SW; Lee SA; Ma HI; Kim YE; Kim ES; Kim YJ; Kim HS; Woo MH; Choi HJ; Kim EY
    Eur Radiol; 2022 May; 32(5):3597-3608. PubMed ID: 35064313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing Nigrosome-1 Sign Identification via Interpretable AI using True Susceptibility Weighted Imaging.
    Wang C; He N; Zhang Y; Li Y; Huang P; Liu Y; Jin Z; Cheng Z; Liu Y; Wang Y; Zhang C; Haacke EM; Chen S; Yan F; Yang G
    J Magn Reson Imaging; 2024 Nov; 60(5):1904-1915. PubMed ID: 38236577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nigrosome 1 visibility and its association with nigrostriatal dopaminergic loss in Parkinson's disease.
    Kim HK; Kim T; Baek MS; Kim EY; Sung YH; Lee JH; Ryu YH; Ahn SJ; Yoo HS; Lyoo CH
    Eur J Neurol; 2023 Jun; 30(6):1639-1647. PubMed ID: 36915220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential involvement of nigral subregions in idiopathic parkinson's disease.
    Sung YH; Lee J; Nam Y; Shin HG; Noh Y; Shin DH; Kim EY
    Hum Brain Mapp; 2018 Jan; 39(1):542-553. PubMed ID: 29064601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deep learning regressor model based on nigrosome MRI in Parkinson syndrome effectively predicts striatal dopamine transporter-SPECT uptake.
    Bae YJ; Choi BS; Kim JM; Ai WA; Yun I; Song YS; Nam Y; Cho SJ; Kim JH
    Neuroradiology; 2023 Jul; 65(7):1101-1109. PubMed ID: 37209181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early-stage Parkinson's disease: Abnormal nigrosome 1 and 2 revealed by a voxelwise analysis of neuromelanin-sensitive MRI.
    Sung YH; Noh Y; Kim EY
    Hum Brain Mapp; 2021 Jun; 42(9):2823-2832. PubMed ID: 33751680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial diagnostic workup of parkinsonism: Dopamine transporter positron emission tomography versus susceptibility map-weighted imaging at 3T.
    Sung YH; Lee J; Nam Y; Shin HG; Noh Y; Hwang KH; Lee H; Kim EY
    Parkinsonism Relat Disord; 2019 May; 62():171-178. PubMed ID: 30580909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging the Nigrosome 1 in the substantia nigra using susceptibility weighted imaging and quantitative susceptibility mapping: An application to Parkinson's disease.
    Cheng Z; He N; Huang P; Li Y; Tang R; Sethi SK; Ghassaban K; Yerramsetty KK; Palutla VK; Chen S; Yan F; Haacke EM
    Neuroimage Clin; 2020; 25():102103. PubMed ID: 31869769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of susceptibility-weighted imaging and susceptibility map-weighted imaging for the diagnosis of Parkinsonism with nigral hyperintensity.
    Bae YJ; Song YS; Choi BS; Kim JM; Nam Y; Kim JH
    Eur J Radiol; 2021 Jan; 134():109398. PubMed ID: 33264728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nigrosome 1 imaging: technical considerations and clinical applications.
    Kim EY; Sung YH; Lee J
    Br J Radiol; 2019 Sep; 92(1101):20180842. PubMed ID: 31067082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determining the Degree of Dopaminergic Denervation Based on the Loss of Nigral Hyperintensity on SMWI in Parkinsonism.
    Bae YJ; Song YS; Kim JM; Choi BS; Nam Y; Choi JH; Lee WW; Kim JH
    AJNR Am J Neuroradiol; 2021 Apr; 42(4):681-687. PubMed ID: 33509919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic resonance imaging evaluation of nigrosome 1 and neuromelanin can assist Parkinson's disease diagnosis, but requires an expert neuroradiologist.
    De Pietro Franco Zorzenon C; Almeida Antônio Bienes GH; Duarte Alves E; Tobaru Tibana LA; Carrete Júnior H; Ballalai Ferraz H
    Parkinsonism Relat Disord; 2021 Feb; 83():8-12. PubMed ID: 33418131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substantia nigra nigrosome-1 imaging correlates with the severity of motor symptoms in Parkinson's disease.
    Chu YT; Yu CF; Fan SP; Chen TF; Chiu MJ; Jang JR; Chiu SI; Lin CH
    J Neurol Sci; 2023 Aug; 451():120731. PubMed ID: 37454574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Swallow tail sign on susceptibility map-weighted imaging (SMWI) for disease diagnosing and severity evaluating in parkinsonism.
    Liu X; Wang N; Chen C; Wu PY; Piao S; Geng D; Li Y
    Acta Radiol; 2021 Feb; 62(2):234-242. PubMed ID: 32380911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Convolutional neural network-based segmentation can help in assessing the substantia nigra in neuromelanin MRI.
    Le Berre A; Kamagata K; Otsuka Y; Andica C; Hatano T; Saccenti L; Ogawa T; Takeshige-Amano H; Wada A; Suzuki M; Hagiwara A; Irie R; Hori M; Oyama G; Shimo Y; Umemura A; Hattori N; Aoki S
    Neuroradiology; 2019 Dec; 61(12):1387-1395. PubMed ID: 31401723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of 3D FLAIR and Dopamine Transporter Imaging in Patients With Parkinsonism.
    Oh SW; Shin NY; Lee JJ; Lee SK; Lee PH; Lim SM; Kim JW
    AJR Am J Roentgenol; 2016 Nov; 207(5):1089-1094. PubMed ID: 27489952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A distinct neuromelanin magnetic resonance imaging pattern in parkinsonian multiple system atrophy.
    Simões RM; Castro Caldas A; Grilo J; Correia D; Guerreiro C; Pita Lobo P; Valadas A; Fabbri M; Correia Guedes L; Coelho M; Rosa MM; Ferreira JJ; Reimão S
    BMC Neurol; 2020 Nov; 20(1):432. PubMed ID: 33243166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.